MHC and the Power of P

Affiliations

¹ Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, National Cancer Institute, National Institutes of Health, MD, USA.

Editorial

Howard Streicher. JNCI Cancer Spectr. 2020.

. 2020 Dec 29;5(1):pkaa116.

doi: 10.1093/jncics/pkaa116. eCollection 2021 Feb.

¹ Division of Cancer Treatment and Diagnosis, Cancer Therapy Evaluation Program, Investigational Drug Branch, National Cancer Institute, National Institutes of Health, MD, USA.

No abstract available

Comment on

Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis.
Iafolla MAJ, Yang C, Chandran V, Pintilie M, Li Q, Bedard PL, Hansen A, Lheureux S, Spreafico A, Razak AA, Hakgor S, Giesler A, Pugh TJ, Siu LL. Iafolla MAJ, et al. JNCI Cancer Spectr. 2020 Dec 29;5(1):pkaa115. doi: 10.1093/jncics/pkaa115. eCollection 2021 Feb. JNCI Cancer Spectr. 2020. PMID: 33554038 Free PMC article. Clinical Trial.

1. Iafolla MAJ, Yang C, Vinod C, et al.Predicting toxicity and response to pembrolizumab through germline genomic HLA class 1 analysis. JNCI Cancer Spectrum. 2021.. doi: 10.1093/jncics/pkaa115. - PMC - PubMed
1. Chowell D, Morris LGT, Grigg CM, et al.Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science. 2018;359(6375):582–587. - PMC - PubMed
1. Stadtmauer E, Fraietta J, Davis M, et al.CRISPR-engineered T cells in patients with refractory cancer. Science. 2020;367(6481):eaba7365. - PMC - PubMed
1. Chowell D, Krishna C, Pierini F, et al.Evolutionary divergence of HLA class I genotype impacts efficacy of cancer immunotherapy. Nat Med. 2019;25(11):1715–1720. - PMC - PubMed
1. Tran E, Robbins P, Rosenberg S.. Final common pathway of human cancer immunotherapy: targeting random somatic mutations. Nat Immunol. 2017;18(3):255–262. - PMC - PubMed